Case Control Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Jun 19, 2024; 14(6): 784-793
Published online Jun 19, 2024. doi: 10.5498/wjp.v14.i6.784
Cognitive dysfunction in schizophrenia patients caused by down-regulation of γ-aminobutyric acid receptor subunits
Xi Chen, Ya-Nan Zhou, Xiao-Zi Lu, Ren-Jiao Li, Yi-Fan Xiong, Xia Sheng, Wei-Wei Zhu
Xi Chen, Ya-Nan Zhou, Ren-Jiao Li, Xia Sheng, Department of Child and Adolescent Psychiatric, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, Changsha 410007, Hunan Province, China
Xiao-Zi Lu, Department of Psychiatry, Qingdao Mental Health Center, Qingdao 266034, Shandong Province, China
Yi-Fan Xiong, Department of Psychiatry, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, Changsha 410007, Hunan Province, China
Wei-Wei Zhu, Department of Sleep Disorders and Neurosis, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, Changsha 410007, Hunan Province, China
Author contributions: Chen X performed the majority of experiments and wrote the manuscript; Zhou YN and Lu XZ designed the study and corrected the manuscript; Li RJ is involved in analytical tools; Xiong YF and Sheng X participated to the collection of the human material; Zhu WW served as scientific advisor and participate to the collection of human material.
Institutional review board statement: The study was approved by the ethics committee of Brain Hospital of Hunan Province (Approval No. 2023338).
Informed consent statement: All patients gave informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at q1640809558@163.com.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Wei Zhu, MM, Associate Chief Physician, Department of Sleep Disorders and Neurosis, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, No. 427, Section 3, Furong Middle Road, Yuhua District, Changsha 410007, Hunan Province, China. q1640809558@163.com
Received: March 7, 2024
Revised: April 25, 2024
Accepted: May 10, 2024
Published online: June 19, 2024
Processing time: 104 Days and 4.3 Hours
Core Tip

Core Tip: The levels of gamma-aminobutyric acid (GABA) receptor subunits differ between the brains of patients with schizophrenia and those of healthy individuals. Patients with schizophrenia show cognitive impairments due to problems with attention, memory, social cognition, and executive functions. Furthermore, downregulation of the GABA receptor subunits GABRA1, GABRB1, GABRD, and GABRE is positively correlated with declining cognitive function in schizophrenia patients. No significant correlation was found between the subunit expression levels of GABRA5 and GABRA6.